109 related articles for article (PubMed ID: 16514179)
1. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.
Donnelly ET; Liu Y; Rockwell S
Exp Biol Med (Maywood); 2006 Mar; 231(3):317-21. PubMed ID: 16514179
[TBL] [Abstract][Full Text] [Related]
2. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
3. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
Hou H; Khan N; Grinberg OY; Yu H; Grinberg SA; Lu S; Demidenko E; Steffen RP; Swartz HM
Radiat Res; 2007 Aug; 168(2):218-25. PubMed ID: 17638413
[TBL] [Abstract][Full Text] [Related]
4. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
5. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
Rockwell S; Kelley M
Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
[TBL] [Abstract][Full Text] [Related]
7. Efaproxiral: a novel radiation sensitiser.
Suh JH
Expert Opin Investig Drugs; 2004 May; 13(5):543-50. PubMed ID: 15155129
[TBL] [Abstract][Full Text] [Related]
8. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
9. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1503-9. PubMed ID: 15817356
[TBL] [Abstract][Full Text] [Related]
10. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
[TBL] [Abstract][Full Text] [Related]
11. Role of efaproxiral in metastatic brain tumors.
Engel RH; Kaklamani VG
Expert Rev Anticancer Ther; 2006 Apr; 6(4):477-85. PubMed ID: 16613536
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
[TBL] [Abstract][Full Text] [Related]
14. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
[TBL] [Abstract][Full Text] [Related]
15. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma.
Kawasoe Y; Yokouchi M; Ueno Y; Iwaya H; Yoshida H; Komiya S
Oncol Rep; 2009 Nov; 22(5):1045-50. PubMed ID: 19787219
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
Amorino GP; Lee H; Holburn GE; Paschal CB; Hercules SK; Shyr Y; Steffen RP; Choy H
Radiat Res; 2001 Sep; 156(3):294-300. PubMed ID: 11500138
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
18. Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing.
Teicher BA; Holden SA; Ara G; Dupuis NP; Goff D
Cancer J Sci Am; 1995; 1(1):43-8. PubMed ID: 9166453
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
[TBL] [Abstract][Full Text] [Related]
20. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
